All In Biotech

Drug Trial Radar · NCT00272948

Pediatric Trial Investigating the Incidence & Outcome of Veno-Occlusive Disease With the Prophylactic Use of Defibrotide

Prospective Randomized Study of the Incidence and Outcome of Veno-Occlusive Disease (VOD) With the Prophylactic Use of Defibrotide (DF) in Pediatric Stem Cell Transplantation

Last checked: Nov 20, 2026Latest source record: Jun 9, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

360

Planned (sponsor's estimate)

Start

Dec 2005

Primary completion

Jan 2009

Study completion Jul 2009

Sponsor

Sponsor type
Research network
Collaborators
Jazz Pharmaceuticals; Deutsche Krebshilfe e.V., Bonn (Germany)
First posted
Jan 9, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this trial is to evaluate whether the prophylactic use of Defibrotide (DF) in pediatric patients (age less than 18 years) undergoing stem cell transplantation and who are at high risk of developing hepatic Veno-occlusive Disease (VOD) will have an impact on the incidence and severity of the disease. Patients will be randomly assigned to one of two treatment arms: Those allocated to the Prophylactic Arm will receive the study drug (Defibrotide) from the day of conditioning onwards. Patients allocated to the Control Arm will receive the study drug (Defibrotide) from the day that VOD is diagnosed.

Conditions

  • Hepatic Veno-Occlusive Disease

Interventions

  • DefibrotideDrug

    Defibrotide 25 mg/kg/d

  • DefibrotideDrug

    Defibrotide 25 mg/kg/d iv in 4 doses beginning at day of conditioning until day +30 or until discharge from inpatient care (with a minimum treatment of 14 days) if VOD does not occur.

  • DefibrotideDrug

    Defibrotide 25 mg/kg/d iv therapeutically when patients fulfil modified Seattle criteria

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary objective is to evaluate if prophylactic DF has an impact on the incidence of VODTime frame: Day + 30 post HSCT

Locations

30 sites in 10 countries. Site status is shown where the registry gives one.

  • University Hospital

    Graz, Austria

  • St Anna Kinderspital

    Vienna, Austria

  • Inst. Gustave Roussy

    Villejuif, France

  • University Hospital

    Dresden, Germany

  • Klinik Kinder-Onkologie

    Düsseldorf, Germany

  • Johann-Wolfgang Goethe Universität

    Frankfurt, Germany

  • Universitätsspital Eppendorf

    Hamburg, Germany

  • Medical School

    Hanover, Germany

  • University Hospital

    Heidelberg, Germany

  • Kinderklinik

    Jena, Germany

  • Christian-Albrecht -University

    Kiel, Germany

  • Kinderpoliklinik Uni

    München, Germany

  • Poliklinik Kinderheilkunde

    Münster, Germany

  • Universitätsspital

    Tübingen, Germany

  • Our Lady's Hospital for Sick Children

    Dublin, Ireland

  • Schneider Children's MC

    Petah Tikva, Israel

  • Institute G. Gaslini

    Genova, Italy

  • Ospedale S. Gerardo

    Monza, Italy

  • Clinica di Oncoematologia Pediatrica

    Padova, Italy

  • University Hospital

    Utrecht, Netherlands

  • Sahlgrenska University Hospital

    Gothenburg, Sweden

  • University Hospital

    Huddinge, Sweden

  • University Hospital

    Lund, Sweden

  • University Hospital

    Uppsala, Sweden

  • University Children Hospital

    Basel, Switzerland

  • Inselspital

    Bern, Switzerland

  • Hopital Cantonal Universitaire

    Geneva, Switzerland

  • University Hospital

    Zurich, Switzerland

  • Great Ormond Street Hospital

    London, United Kingdom

  • Children's Hospital

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.